Direct answer. Mitral valve prolapse occurs when one or both mitral leaflets bulge into the left atrium during contraction. It does not always cause regurgitation or symptoms. Important leakage and, in selected people, rhythm findings need their own assessment rather than assumptions from the word prolapse. Confidence is high in the anatomical distinction; no universal supplement or intervention regimen is established by this focused independent review. NHLBI valve anatomy and types, March 2022.
- Prolapse describes leaflet movement; regurgitation describes backward flow.
- Many people have no important leakage, while others need monitoring for a specific valve problem.
- Palpitations or fainting require assessment rather than automatic attribution to prolapse or anxiety.
- Selected arrhythmic presentations differ from an uncomplicated incidental finding.
- Treatment follows documented leakage, rhythm or other disease; the label alone does not justify a procedure.
Evidence summary
| Question | Source role | Conclusion and confidence |
|---|---|---|
| Does every prolapse leak? | NHLBI public anatomy | No. Prolapse and regurgitation are different findings. High confidence. |
| Does every palpitation come from it? | Clinical diagnostic context | No. Symptoms and documented rhythm need assessment. |
| Is all prolapse harmless or high risk? | Public and specialist distinctions | Neither blanket claim is justified; anatomy, leakage and selected rhythm findings differ. |
| Which treatment applies? | Attributed care context | Treat established complications and indications, not the label alone. |
Confidence is high in the condition distinctions and need for appropriate assessment. The treatment section attributes clinical guidance; it does not certify the funding of every underlying intervention trial. Independent comparative outcome certainty and a supplement replacement regimen were not established by this focused review. A public institution or independent review cannot make a sponsored original trial financially independent.
What it is
The mitral valve separates the left atrium and left ventricle. It should close while the ventricle contracts. In prolapse, one or both leaflets move back into the atrium. That is an anatomical description. Leakage occurs if the valve does not make an adequate seal, but the two observations are not interchangeable. NHLBI valve anatomy and types, March 2022.
The public NHLBI explanation notes that prolapse often occurs without related leakage or symptoms. That helps prevent unnecessary alarm, but it should not be turned into a guarantee that every person’s finding is inconsequential. The relevant questions are how the leaflets and supporting structures look, whether important regurgitation is present and what other cardiac findings accompany them. NHLBI valve anatomy and types, March 2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
A murmur or imaging can lead to detection. Some people report palpitations, fatigue, chest symptoms or exercise limitation, but those experiences do not prove that prolapse is their cause. A prior scan label should neither dismiss new symptoms nor make all symptoms a valve complication. History, examination, imaging and selected rhythm testing provide different information. NHLBI valve disease symptoms, March 2022; NHLBI valve disease diagnosis, March 2022.
How it works
Leaflet and supporting-tissue abnormalities can interfere with normal closure. Degenerative changes range in extent and can affect the likelihood and mechanism of regurgitation. If significant chronic leakage develops, left-sided chambers and pulmonary pressures can be affected over time. If there is no important leak, those consequences should not be assumed from leaflet movement alone. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
The 2025 guideline also recognizes a small subgroup of primary mitral disease with ventricular arrhythmic features. Mitral annular disjunction and selected tissue or rhythm findings can be relevant to that assessment, and arrhythmic burden is not simply predicted by regurgitation severity. This does not mean that every incidental prolapse requires the same tests or carries the same risk. Specialist interpretation is needed. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Echocardiography establishes valve anatomy and function and assesses cardiac consequences. Selected ambulatory rhythm monitoring or cardiac MRI can address a particular symptom or risk question. A wearable alert does not diagnose an arrhythmic prolapse syndrome, while a short normal tracing may not settle intermittent symptoms. The plan should state what was assessed, what remains uncertain and whether further testing has an indication. NHLBI valve disease diagnosis, March 2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
The evidence-based treatments
A finding without important leakage or another established complication may need education and an appropriate review plan rather than medication or surgery. The clinician should explain whether any surveillance is needed for the actual anatomy and function. There is no treatment here intended merely to change an incidental leaflet-motion label or an unsupported “weak connective tissue” diagnosis. NHLBI valve anatomy and types, March 2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
If significant primary mitral regurgitation develops, management follows its severity, symptoms and cardiac effects. The current guidance describes selected surgical repair, replacement or catheter treatment according to anatomy, expected durability, operative suitability and patient preferences. Those are attributed care options; the guide does not certify every underlying device study as financially independent or rank manufacturers. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
If a clinically important arrhythmia is documented, it needs a separate rhythm-specific assessment. A medicine, monitoring strategy or device should have an explicit indication, not be prescribed because all prolapse is assumed to behave the same way. Conversely, uncomplicated leaflet motion should not be used to dismiss fainting or a concerning arrhythmia history without appropriate review. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
After an intervention, residual leakage, altered valve opening, ventricular response and rhythm can still need monitoring. The procedure’s result and the underlying disease are related but separate. Ask which problem the intervention addressed and which findings require continuing care; a successful repair does not automatically settle every symptom or future medication question. NHLBI valve care background, March 2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Supplement and lifestyle evidence
Discuss activity according to current valve function, symptoms and any established rhythm findings. An uncomplicated incidental finding and important regurgitation may need different advice. General cardiovascular care, smoking avoidance and reviewing stimulant or recreational-drug exposure support health; improvement after avoiding a trigger does not prove that the valve anatomy has changed or that every symptom came from it. NHLBI valve care background, March 2022.
No supplement is established here as a treatment for mitral valve prolapse. “Heart support,” improved vessel relaxation, a changed blood marker and fewer clinical events are different claims. The cited source set does not provide a fully financially screened trial basis for replacing diagnosis or prescribed care. Correcting a clinician-confirmed deficiency is a separate indication; a retail blend is not a diagnostic test or an emergency treatment.
What works and what does not
Useful care avoids both blanket reassurance and blanket alarm. It distinguishes leaflet motion, leak severity, rhythm findings and symptom explanations and records which of those needs follow-up. A changed wearable reading, softer murmur or reduced palpitations is not a complete reassessment of all valve and rhythm questions. The independent evidence boundary also prevents a retail supplement claim from becoming a replacement-care recommendation. NHLBI valve disease diagnosis, March 2022.
Ask which outcome is being pursued: symptoms, physiological findings, recurrence, hospital admission or survival. A plan should also say how adverse effects and deterioration will be recognized. Personal stories and before-and-after readings cannot separate treatment effects from the natural course, other medicines or selection of patients. Manufacturer or materially conflicted outcome claims do not determine this article’s independent verdict.
Risks and side effects
Severe breathlessness, collapse or new concerning chest pain needs emergency help. Fainting, sustained symptomatic palpitations or a major new decline in capacity warrants prompt assessment according to severity. Do not continue exertion to prove a symptom is benign or assume that a previous prolapse diagnosis explains the episode. NHS current national heart valve disease education.
The relevant disease risks depend on actual leakage, cardiac consequences and selected rhythm findings. Treatments have separate risks: cardiac medicines can affect rate, pressure, kidney function or electrolytes; anticoagulants can cause bleeding; procedures can cause infection, stroke, bleeding, injury or residual valve dysfunction. A discussion should explain why the proposed intervention is appropriate for the documented problem. NHLBI valve care background, March 2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Important interactions
If a rate/rhythm medicine, diuretic or anticoagulant has been prescribed for a documented indication, review other medicines and supplements with the responsible service. Do not borrow a beta-blocker, start an “anti-palpitations” blend or stop prescribed care because prolapse is often uncomplicated. Before pregnancy or a procedure, clarify the actual valve severity, previous intervention and medication list. NHLBI valve disease and pregnancy, March 2022; NHLBI valve care background, March 2022.
Bring prescription medicines, non-prescription products, recreational drugs and supplements to the same medication review. Product names alone may hide several active ingredients. The prescriber or pharmacist should check the exact combination and kidney function, rather than treating “natural” as a safety category. Never add a second person’s rescue medicine or stop an important prescribed medicine because an internet list mentions a possible interaction.
Who needs assessment
Ask what the scan established about leaflet movement, supporting anatomy and regurgitation, whether the chambers or pressures are affected, and whether symptoms justify rhythm investigation. An old or incomplete report should not be interpreted as an all-purpose explanation. Additional imaging or monitoring should answer a defined question, rather than being bought as a universal prolapse package. NHLBI valve disease diagnosis, March 2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Pregnancy planning, a previous valve intervention, kidney disease and anticoagulant use deserve specific review. The current status of the valve matters more than an old diagnostic label. Children with congenital disease need an age-appropriate specialist pathway rather than an adult intervention rule. NHLBI valve disease and pregnancy, March 2022.
Clinician-led use and follow-up
Ask whether repeat imaging or rhythm monitoring is indicated, when it should occur and which symptoms should prompt earlier contact. For significant regurgitation or an arrhythmic presentation, request a specific care plan rather than generic prolapse advice. No personal medicine dose, self-diagnostic imaging criterion or universal exercise restriction is provided here; the established findings should guide review. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
This guide gives no personal drug, device or supplement dose. The appropriate plan depends on the established diagnosis, current stability, other illnesses and local services. Ask for a written explanation of the treatment purpose, warning signs, review schedule and contact route for side effects. Clinical monitoring and informed consent should accompany any change; study exposures are not prescriptions.
Animal and in-vitro evidence
Laboratory work on valve calcification, connective tissue or blood-flow mechanics can help investigate a mechanism. It cannot determine a safe human supplement dose, establish that a calcified valve will reopen, or select an implant for an individual. An animal or cell finding does not replace a clinical assessment of anatomy, severity and complications. No animal or in-vitro result contributes to this guide’s independent clinical verdict.
Funding and source roles
Research funding at a glance
19 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
Financial interests include echocardiography and advanced imaging, valve implants, surgical and catheter services, medicines and marketed supplements. Valve-device manufacturers and professional societies can have relevant financial relationships even when the document itself reports no direct industry-development funding. Those routes and unresolved author/trial chains are shown below; no manufacturer or materially conflicted outcome claim establishes this guide’s independent verdict.
The condition has no corporate owner. Medicines, diagnostics, devices, procedures and marketed supplements create different revenue incentives. This describes financial interests rather than misconduct. Funding tier evaluates proximity to the subject; A–D credibility assesses transparency, accuracy incentives and remaining uncertainty. An unresolved link stays unresolved, and a provisional public-information label does not clear the trials behind it.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHLBI valve anatomy and types, March 2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Dated public anatomy and distinctions between stenosis, regurgitation and prolapse. |
| NHLBI valve disease causes, March 2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Dated public inherited and acquired contributor education. |
| NHLBI valve disease symptoms, March 2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Public symptom education; symptoms do not establish severity. |
| NHLBI valve disease diagnosis, March 2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Clinical investigation background; no self-diagnostic thresholds. |
| NHLBI valve care background, March 2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Dated public procedure/adverse-effect background; oversimplified tissue-valve anticoagulation wording not reproduced. |
| NHS current national heart valve disease education | DHSC funds the national NHS website; its policy states no advertising or corporate sponsorship. Named authors, page-level budget and full underlying trial conflicts unresolved. | United Kingdom; England national public-information service. Other jurisdictions have different services. | Tier 1 public education provisional; not a clearance of original studies. | B provisional. Public-service remit and editorial checks support accuracy; simplification, service priorities and incomplete trial-finance tracing limit inference. Role: January 2025 national condition and emergency education; broad prolapse wording not reproduced. |
| Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF | The original guideline states document development was financed entirely by ESC and EACTS without healthcare-industry involvement. ESC institutional revenues nevertheless include life-science and medtech partnerships; EACTS discloses industry/charity grants and an Edwards Lifesciences Foundation partnership. That separate route does not prove Edwards funded this guideline. The official 2025 author declaration report returned 403 and was not read. Article allocation, individual author independence and original device/drug trial chains remain unresolved. | France: ESC, Sophia Antipolis. United Kingdom: EACTS, Windsor, registered England and Wales; OUP publisher UK. International writing panel. The unchanged original EJCTS PDF mirror is hosted by MATCVS, Malaysia; it does not change the document author or funding origin. Edwards corporate headquarters Irvine, California, US; specific supplied-device manufacturing origin unresolved. | Tier 2 documented society industry routes, with unresolved author chain; independent efficacy excluded. | C provisional. Original 109-page guideline and August 2026 correction checked. Detailed methodology, specialist review and explicit evidence grades aid attributed clinical use; society commercial routes, inaccessible author declarations and uncleared original-trial finances prevent a clean independent outcome verdict. Role: Current 2025 specialist care context with August 2026 correction checked; C provisional, not independent efficacy. |
| NHLBI valve disease and pregnancy, March 2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Pregnancy planning when clinically important valve disease or previous intervention is present. |
| NHLBI valve disease definitions, March 2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Additional original linked in condition-specific education or follow-up. |
| NHLBI budget | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
| NHLBI Gift Fund | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
| NHS national website funding policy | DHSC funds the national NHS website; its policy states no advertising or corporate sponsorship. Named authors, page-level budget and full underlying trial conflicts unresolved. | United Kingdom; England national public-information service. Other jurisdictions have different services. | Tier 3 editorial and financial self-disclosure. | B provisional. Explicit funding policy; actual individual declarations and implementation not audited. Financial provenance only. |
| ESC funding and revenue model | ESC directly reports life-science and medtech partnership income alongside memberships, congresses, publishing and education. Its July 2026 policy manages industry remuneration and other interests; reporting a policy is not proof that all bias is removed. | France; ESC European Heart House, Sophia Antipolis; multinational professional society. | Tier 3 institutional self-disclosure; financially interested in its own governance description. | B provisional for stated revenue routes; C where relied on to certify its own clinical independence. Financial transparency supports checking; actual amounts, implementation and document allocations not audited. Financial provenance only. |
| ESC conflict management policy | ESC directly reports life-science and medtech partnership income alongside memberships, congresses, publishing and education. Its July 2026 policy manages industry remuneration and other interests; reporting a policy is not proof that all bias is removed. | France; ESC European Heart House, Sophia Antipolis; multinational professional society. | Tier 3 institutional self-disclosure; financially interested in its own governance description. | B provisional for stated revenue routes; C where relied on to certify its own clinical independence. Financial transparency supports checking; actual amounts, implementation and document allocations not audited. Financial provenance only. |
| EACTS current industry/charity grant and Edwards Foundation relationship | EACTS explicitly offers industry/charity-sponsored outreach grants and names Edwards Lifesciences Foundation for Every Heartbeat Matters; a separate industry-sponsorship contact is provided. Edwards confirms funding, product donations and matching-gift routes. EACTS annual revenue amounts, complete donor list, guideline allocation and individual author finances were not fully traced. This is a documented institutional relationship, not evidence that Edwards directly financed the valve guideline. | United Kingdom; EACTS House, Windsor, registered company and charity in England and Wales. Edwards corporate headquarters Irvine, California, United States; global manufacturing locations differ from grant or guideline jurisdiction. | Tier 3 institutional financial self-disclosure; society has a stake in its own governance description. | B provisional for documented relationships and registered contact; C if used to certify clinical independence. Direct named support improves transparency; amounts, contract terms, full donor and page/author chains remain unresolved. Financial provenance only. |
| EACTS industry sponsorship route | EACTS explicitly offers industry/charity-sponsored outreach grants and names Edwards Lifesciences Foundation for Every Heartbeat Matters; a separate industry-sponsorship contact is provided. Edwards confirms funding, product donations and matching-gift routes. EACTS annual revenue amounts, complete donor list, guideline allocation and individual author finances were not fully traced. This is a documented institutional relationship, not evidence that Edwards directly financed the valve guideline. | United Kingdom; EACTS House, Windsor, registered company and charity in England and Wales. Edwards corporate headquarters Irvine, California, United States; global manufacturing locations differ from grant or guideline jurisdiction. | Tier 3 institutional financial self-disclosure; society has a stake in its own governance description. | B provisional for documented relationships and registered contact; C if used to certify clinical independence. Direct named support improves transparency; amounts, contract terms, full donor and page/author chains remain unresolved. Financial provenance only. |
| EACTS registered jurisdiction and Windsor contact | EACTS explicitly offers industry/charity-sponsored outreach grants and names Edwards Lifesciences Foundation for Every Heartbeat Matters; a separate industry-sponsorship contact is provided. Edwards confirms funding, product donations and matching-gift routes. EACTS annual revenue amounts, complete donor list, guideline allocation and individual author finances were not fully traced. This is a documented institutional relationship, not evidence that Edwards directly financed the valve guideline. | United Kingdom; EACTS House, Windsor, registered company and charity in England and Wales. Edwards corporate headquarters Irvine, California, United States; global manufacturing locations differ from grant or guideline jurisdiction. | Tier 3 institutional financial self-disclosure; society has a stake in its own governance description. | B provisional for documented relationships and registered contact; C if used to certify clinical independence. Direct named support improves transparency; amounts, contract terms, full donor and page/author chains remain unresolved. Financial provenance only. |
| Edwards corporate/foundation funding and technology-donation routes | Edwards Lifesciences corporate/foundation self-disclosure. It describes charitable funding, technology donations, employee matching and annual recipients. Corporate device sales and reputation create a direct interest; no corporate clinical outcome claim is used as independent evidence. Foundation-wide donors, grant contract terms and specific product provenance were not audited. | United States; Edwards Lifesciences corporate global headquarters Irvine, California. The opened location page names US manufacturing and says manufacturing is multinational; a headquarters is not the origin of every implant. | Tier 4 maker-associated corporate/foundation self-disclosure; clinical outcome claims excluded. | D for clinical promotion; provisional B only for explicit self-reported addresses and funding routes cross-checked with EACTS. Commercial and reputational incentives remain. Financial provenance only. |
| Edwards global headquarters and manufacturing-location disclosure | Edwards Lifesciences corporate/foundation self-disclosure. It describes charitable funding, technology donations, employee matching and annual recipients. Corporate device sales and reputation create a direct interest; no corporate clinical outcome claim is used as independent evidence. Foundation-wide donors, grant contract terms and specific product provenance were not audited. | United States; Edwards Lifesciences corporate global headquarters Irvine, California. The opened location page names US manufacturing and says manufacturing is multinational; a headquarters is not the origin of every implant. | Tier 4 maker-associated corporate/foundation self-disclosure; clinical outcome claims excluded. | D for clinical promotion; provisional B only for explicit self-reported addresses and funding routes cross-checked with EACTS. Commercial and reputational incentives remain. Financial provenance only. |
Frequently asked questions
Is prolapse the same as a leaky valve? No. Prolapse can occur without important backward flow. NHLBI valve anatomy and types, March 2022.
Does it explain all my palpitations? Not automatically. A rhythm record and clinical assessment are needed to connect symptoms to a specific rhythm or mechanism. NHLBI valve disease diagnosis, March 2022.
Can it ever matter despite only a small leak? Selected arrhythmic findings need their own assessment; this is different from assigning every person with prolapse a high-risk label. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Should I take antibiotics or blood thinners just for prolapse? A medicine needs a specific documented prevention or treatment indication. Do not self-start leftover antibiotics, aspirin or anticoagulation from the anatomical label. NHLBI valve care background, March 2022.
Sources and funding notes
- NHLBI valve anatomy and types, March 2022 — Dated public anatomy and distinctions between stenosis, regurgitation and prolapse.
- NHLBI valve disease causes, March 2022 — Dated public inherited and acquired contributor education.
- NHLBI valve disease symptoms, March 2022 — Public symptom education; symptoms do not establish severity.
- NHLBI valve disease diagnosis, March 2022 — Clinical investigation background; no self-diagnostic thresholds.
- NHLBI valve care background, March 2022 — Dated public procedure/adverse-effect background; oversimplified tissue-valve anticoagulation wording not reproduced.
- NHS current national heart valve disease education — January 2025 national condition and emergency education; broad prolapse wording not reproduced.
- Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF — Current 2025 specialist care context with August 2026 correction checked; C provisional, not independent efficacy.
- NHLBI valve disease and pregnancy, March 2022 — Pregnancy planning when clinically important valve disease or previous intervention is present.
- NHLBI valve disease definitions, March 2022 — Additional original linked in condition-specific education or follow-up.
- NHLBI budget — Financial provenance only.
- NHLBI Gift Fund — Financial provenance only.
- NHS national website funding policy — Financial provenance only.
- ESC funding and revenue model — Financial provenance only.
- ESC conflict management policy — Financial provenance only.
- EACTS current industry/charity grant and Edwards Foundation relationship — Financial provenance only.
- EACTS industry sponsorship route — Financial provenance only.
- EACTS registered jurisdiction and Windsor contact — Financial provenance only.
- Edwards corporate/foundation funding and technology-donation routes — Financial provenance only.
- Edwards global headquarters and manufacturing-location disclosure — Financial provenance only.
Original clinical pages and their relevant financial disclosures were opened. The original 109-page 2025 ESC/EACTS valve guideline was read from MATCVS’s unchanged EJCTS/OUP PDF mirror, with its title, authors and DOI verified. The official August 6, 2026 correction was opened separately. The official author-declaration PDF returned 403 and was not read. Actual ESC, EACTS and Edwards financial-route disclosures were checked; separate institutional industry support does not establish direct industry financing of this document. Individual author and original-trial financial chains remain unresolved; clinical recommendations are C-provisional context. Clinical sources concentrate on US and English public education plus European professional guidance. This limits jurisdictional breadth: referral, implant availability and treatment systems vary, and no global access claim is inferred. Guidance, classification, emergency education and independent efficacy are distinct source roles. A full systematic review, complete society donor audit and author-by-author clearance of original treatment trials were not completed.
Last reviewed: October 4, 2026. Educational information, not a diagnosis or personal treatment plan. Use your local emergency service for an emergency.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.